Yangzijiang Shipbuilding (SGX:BS6) stock slips near 52-week high as traders eye March results

Yangzijiang Shipbuilding (SGX:BS6) stock slips near 52-week high as traders eye March results

SINGAPORE, Jan 8, 2026, 15:50 SGT — Regular session

  • Shares fell 0.8% after a three-day rise that pushed the stock to a 52-week peak
  • Phillip Securities Research flagged a “technical buy” call with S$3.48 as a key downside level
  • Investors are watching the next results update and new contract wins

Shares of Yangzijiang Shipbuilding (Holdings) slipped 0.8% to S$3.61 by 3:39 p.m. in Singapore, pulling back after Wednesday’s close at S$3.64 and a session high of S$3.68, which matched the stock’s 52-week peak. The shares traded between S$3.60 and S$3.67 on the day, with turnover at about 8.2 million shares by mid-afternoon. SG Investors

The move comes with investors still leaning on the company’s recent margin story. In its latest half-year report, Yangzijiang said net profit rose 36.7% to RMB4.2 billion for the six months ended June 30, 2025, while shipbuilding gross margin hit a “record high” of 35% and net cash stood at RMB18.3 billion. Executive Chairman and CEO Ren Letian said the group remained “focused on executing our robust orderbook with high-quality and timely delivery.” SGX Links

Chart-watchers have been busy, too. In a Thursday “trade of the day” note, Phillip Securities Research technical analyst Zane Aw tagged the stock as a “TECHNICAL BUY” and flagged S$3.48 as a stop-loss level, with S$4.14 as a take-profit marker. A stop-loss is a preset sell level that traders use to cap losses if a price drops. StocksBnB

On fundamentals, Yangzijiang has pointed to fresh work lined up beyond 2026. In an Aug. 29, 2025 filing, the company said it had secured 22 additional shipbuilding contracts worth an aggregate US$0.92 billion, including 18 containerships and two 40,000 CBM (cubic metre) LPG carriers, with deliveries scheduled between 2027 and 2029. It added the contracts were not expected to have a significant impact on earnings for the year ending Dec. 31, 2025. SGX Links

The near-term question for the stock is whether buyers keep defending pullbacks after a sharp start to 2026, or whether the rally runs out of steam as volumes thin and traders turn cautious ahead of the next data point from management.

But contract risk has not gone away. The group said in a Sept. 27, 2025 announcement that three subsidiaries terminated contracts for four 50,000 DWT (deadweight tonnage) medium-range oil tankers worth about US$180 million after the buyer disclosed allegations linked to a scheme to circumvent U.S. sanctions; the company said the termination was not expected to have a material impact on 2025 earnings per share. SGX Links

Stock Market Today

  • Halozyme Therapeutics appears undervalued on DCF and P/E signals
    January 10, 2026, 3:45 AM EST. Halozyme Therapeutics trades at $72.45, with 7-day, 30-day and 1-year gains shaping investor expectations. A Discounted Cash Flow model using a 2-stage Free Cash Flow to Equity framework puts the intrinsic value around $201.82 per share, about 64% above the current price, suggesting the stock is undervalued. The company's P/E ratio of 14.31x sits below the Biotechs industry average of 21.08x, reinforcing the valuation gap. Halozyme carries a value score of 5 out of 6 in the assessment, with recent licensing and partnership updates providing context for earnings visibility. While DCF signals upside, outcomes depend on execution of collaborations and regulatory timing, keeping risk balanced against potential payoff.
OCBC stock back near record highs as dividend buyers crowd into Singapore banks
Previous Story

OCBC stock back near record highs as dividend buyers crowd into Singapore banks

CapitaLand Investment stock climbs after S$260 million Singapore automated logistics bet
Next Story

CapitaLand Investment stock climbs after S$260 million Singapore automated logistics bet

Go toTop